期刊文献+

抗肿瘤活性化合物SM-1的有关物质检查方法研究 被引量:2

Examination method of related substances of anti-tumor compound SM-1
原文传递
导出
摘要 目的:建立高效液相色谱法检查SM-1的有关物质,为SM-1质量控制提供参考。方法:采用ZORBAX Eclipse XDB-C18柱(250 mm×4.6 mm,5μm)为色谱柱,以0.01 mol·L^(-1)磷酸盐缓冲液[(取0.01mol磷酸氢二钾,加水溶解并稀释至1 000 m L,用磷酸调节p H至(7.0±0.02)]为流动相A,以乙腈为流动相B,梯度洗脱,检测波长210 nm(L2、杂质B及自身对照中的SM-1)和325 nm(SM-1、ABT-D、杂质A及未知杂质)。结果:在上述色谱条件下,SM-1与各副产物及降解产物均能有效分离,杂质L2、ABT-D、杂质A及杂质B的检测限分别为33,15,40,33 ng·m L^(-1)。结论:该方法专属性强、准确、灵敏,可用于SM-1原料药有关物质的检测分析及质量控制。 Objective:To establish an HPLC method for the examination of related substances of SM-1,in order to provide information for the quality control of SM-1. Methods:A ZORBAX Eclipse XDB-C18column(250 mm × 4. 6 mm,5 μm) was used. The mobile phase consisted of solvent A(0. 01 mol·L^-1potassium hydrogen phosphate soulution,p H adjusted to 7. 0 ± 0. 02 by phosphate) and solvent B(acetonitrile). Gradient elution was adopted. The detection wavelengths were set at 210 nm for related substances L2,B and SM-1 for self-control and325 nm for SM-1,related substances ABT-D,A and unknown related substances,respectively. Results:SM-1 could be separated well with its side products and degradation products. The limits of detection for the related substances L2,ABT-D,A and B were 33,15,40 and 33 ng·m L^-1,respectively. Conclusion:The method is specific,accurate,and sensitive; it can be used for the determination of the related substances of SM-1.
作者 刘珍 梁丰 康志娇 丁劲松 LIU Zhen LIANG Feng KANG Zhi-jiao DING Jin-song(School of Pharmaceutical Sciences, Central South University, Changsha 410013, China Changsha King-eagle Medicine Science & Technology Co. ,Ltd. , Changsha 410205, China)
出处 《中国新药杂志》 CAS CSCD 北大核心 2017年第3期279-284,共6页 Chinese Journal of New Drugs
基金 国家"重大新药创制"科技重大专项资助项目(2012ZX09103101-051)
关键词 SM-1 有关物质 L2 ABT-D 高效液相色谱 SM-1 related substances L2 ABT-D HPLC
  • 相关文献

参考文献3

二级参考文献26

  • 1谢沐风.药物溶液稳定性试验的验证方法与重要性[J].药物分析杂志,2005,25(1):107-109. 被引量:27
  • 2周海钧译.药品注册的国际技术要求(质量部分)[M].北京:人民卫生出版社,2000.
  • 3FDA.Office of generic drugs[EB/OL].[2006-01-31].http://www.fda.gov/cder/ogd
  • 4NORDLANDER M ,SJOQUIST PO ,ERICSSON H,et al. Pharma- codynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure con- trol[ J ]. Cardiovase Drug Rev ,2004,22 (3) :227 - 250.
  • 5VUYLSTEKE A, MILNER Q, ERICEEON H, et al. Pharmacoki- netics and pulmonary extraction of clevidipine,a new vasodilating ultrashort-acting dihydropyridine, during cardiopulmonary bypass [J]. Br J Anaesth ,2000 ,85 ( 5 ) :683 - 689.
  • 6NGUYEN HM,MA K, PHAM DQ. Clevidipine for the treatment of severe hypertension in adults [ J ]. Clin Ther, 2010,32 ( 1 ) : 11 -23.
  • 7ERICSSON H, FAKT C, HOGLUND L, et al, Pharmacokineties and pharmaeodynamics of clevidipine in healthy volunteers after intravenous infusion [ J ]. Eur J Clin Pharmacol, 1999,55 ( 3 ) : 61 - 67.
  • 8HEINIG R. Clinical Pharmacokinetics of nisoldipine coat-core [ J ]. Clin Pharmacokinet, 1998,35 (3) : 191 - 208.
  • 9BARCHIELLI M, DOLFINI E, FARINA P,et al. Clinical phar- macokinefics of lercanidipine [ J ]. J Cardiovasc Pharmacol, 1997,29(2) :1 - 15.
  • 10KENYON KW. Clevidipine : an ultra short-acting calcium channel antagonist for acute hypertension [ J ]. Ann Pharmaco, 2009,43 (7) :1258 -1265.

共引文献66

同被引文献10

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部